Outlook Therapeutics, Inc. (NASDAQ:OTLK) Given Consensus Rating of “Moderate Buy” by Analysts
Outlook Therapeutics, Inc. (NASDAQ:OTLK – Get Free Report) has been assigned an average recommendation of “Moderate Buy” from the six analysts that are currently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average twelve-month price target […]
Outlook Therapeutics, Inc. (NASDAQ:OTLK – Get Free Report) has been assigned an average recommendation of “Moderate Buy” from the six analysts that are currently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average twelve-month price target […]
